| Literature DB >> 35111332 |
Inmaculada Carmen Lara-Palomo1, Eduardo Antequera-Soler1, Guillermo A Matarán-Peñarrocha2, Manuel Fernández-Sánchez1, Héctor García-López1, Adelaida María Castro-Sánchez1, María Encarnación Aguilar-Ferrándiz3.
Abstract
OBJETIVE: We conducted a randomized double blind clinical trial, to compare the effectiveness of McKenzie exercises and electroanalgesia via an e-Health program versus a home rehabilitation program on functionality, pain, fear of movement and quality of life in patients with non-specific chronic low back pain.Entities:
Keywords: Chronic low back pain; McKenzie exercises; general; home rehabilitation; randomized controlled trial; telemedicine; transcutaneous electrical nerve stimulation
Year: 2022 PMID: 35111332 PMCID: PMC8801654 DOI: 10.1177/20552076221074482
Source DB: PubMed Journal: Digit Health ISSN: 2055-2076
Figure 1.Brief outline of the design of the trial.
Figure 2.Protocol of mcKenzie exercise and transcutaneous electrical nerve stimulation. (A) Transcutaneous electrical nerve stimulation (80 Hz/200 µs) applied directly in the lumbar area by four electrodes (5 × 9 cm) at the paravertebral level bilateral. (B) Patients with Postural Syndrome: Exercises 1, 2 and 3. (C) Patients with Dysfunction Syndrome: Exercises 3, 6 and 7. (D) Patients with Derangement Syndrome (DS): Exercises 1 to 10 (according to type of derangement syndrome).
Baseline demographic data of patients.
| Parameters | Baseline | Pre | |
|---|---|---|---|
| E-health program (n = 39) | Home program (n = 35) | ||
| Gender (m/f) | 17/22 | 14/21 | 0.543 |
| Age (y) (Mean ± SD) | 41.9 ± 9.4 | 54.6 ± 12.9 | 0.097 |
| Level of studies | |||
| Primary | 5 | 7 | |
| High school or institute | 15 | 11 | |
| University studies | 19 | 17 | |
| McKenzie classification | |||
| 0 | 0 | ||
| 9 | 11 | ||
| 30 | 24 | ||
p-value of 0.05.
Outcome measures for subjects by groups and time.
| Outcome/group | e-health program (n = 39) | Home rehabilitation program (n = 35) | Inter-group difference in score change | Cohen’s d | |
|---|---|---|---|---|---|
| RMD (0–24) | |||||
| Baseline | 9.92 ± 4.35 | 9 ± 3.98 | 0.92 (−1.01, 2.86) | 0.346 | |
| Post-treatment | 2.49 ± 2.19 | 7.03 ± 4.59 | −4.54 (−6.18, −2.90) | 0.001
| 1.16 |
| ODI (0–50) | |||||
| Baseline | 17.53 ± 11.91 | 21.80 ± 11.63 | −4.26 (−9.73, 1.21) | 0.125 | |
| Post-treatment | 6.10 ± 5.76 | 16.71 ± 10.07 | −10.61 (−14.36, −6.85) | 0.001
| 1.16 |
| VAS (0–10 points) | |||||
| Baseline | 6.72 ± 1.29 | 6.71 ± 1.15 | 0.00 (−0.56, 0.57) | 0.990 | |
| Post-treatment | 2.20 ± 1.39 | 4.48 ± 2.03 | −2.28 (−3.08, −1.48) | 0.001
| 1.14 |
| TSK (17–68) | |||||
| Baseline | 37.64 ± 8.07 | 34.40 ± 8.73 | 3.24 (−0.65, 7.13) | 0.101 | |
| Post-treatment | 27.59 ± 6.68 | 30.00 ± 8.02 | −2.41 (−5.82, 0.99) | 0.163 | 0.28 |
| Quality of life SF-36/group (0–100) | |||||
| Physical function | |||||
| Baseline | 76.41 ± 16.58 | 72.14 ± 11.39 | 4.27 (−2.40, 10.94) | 0.206 | |
| Post-treatment | 93.08 ± 8.71 | 81.43 ± 12.28 | 11.64 (6.75, 16.54) | 0.001
| 0.95 |
| Physical role | |||||
| Baseline | 58.72 ± 21.29 | 59.57 ± 18.60 | −0.85 (−10.17, 8.46) | 0.856 | |
| Post-treatment | 89.48 ± 17.00 | 77.86 ± 16.90 | 11.63 (3.76, 19.50) | 0.004
| 0.56 |
| Body pain | |||||
| Baseline | 59.83 ± 19.84 | 53.21 ± 14.93 | 6.62 (−1.59, 14.83) | 0.113 | |
| Post-treatment | 72.45 ± 17.97 | 68.78 ± 13.38 | 3.66 (−3.75, 11.07) | 0.328 | 0.18 |
| General health | |||||
| Baseline | 65.89 ± 17.01 | 63.28 ± 14.85 | 2.61 (−4.83, 10.05) | 0.486 | |
| Post-treatment | 67.41 ± 17.86 | 68.28 ± 15.24 | −0.87 (−8.61, 6.86) | 0.822 | 0.04 |
| Vitality | |||||
| Baseline | 61.28 ± 14.35 | 67.28 ± 13.79 | −6.00 (−12.54, 0.53) | 0.071 | |
| Post-treatment | 82.82 ± 12.24 | 70.57 ± 12.59 | 12.25 (6.49, 18.01) | 0.001
| 0.81 |
| Social functioning | |||||
| Baseline | 78.51 ± 22.60 | 71.78 ± 16.69 | 6.73 (−2.57, 16.02) | 0.154 | |
| Post-treatment | 86.86 ± 19.23 | 75.00 ± 17.41 | 11.86 (3.32, 20.39) | 0.007
| 0.52 |
| Emotional role | |||||
| Baseline | 71.54 ± 26.85 | 76.72 ± 24.94 | −5.17 (−17.23, 6.88) | 0.395 | |
| Post-treatment | 94.88 ± 12.17 | 85.71 ± 23.27 | 9.16 (0.68, 17.64) | 0.035
| 0.45 |
| Mental health | |||||
| Baseline | 71.43 ± 13.85 | 74.63 ± 11.43 | −3.19 (−9.12, 2.73) | 0.286 | |
| Post-treatment | 93.64 ± 7.98 | 80.34 ± 10.59 | 13.29 (8.97, 17.62) | 0.001
| 1.22 |
| Physical measurements | |||||
| McQuade test (s) | |||||
| Baseline | 46.28 ± 13.82 | 42.71 ± 11.14 | 3.57 (−2.29, 9.43) | 0.229 | |
| Post-treatment | 63.38 ± 17.58 | 60.48 ± 9.12 | 2.89 (−3.70, 9.50) | 0.384 | 0.15 |
| Lumbar flexion mobility (cm) | |||||
| Baseline | 19.15 ± 13.83 | 16.36 ± 8.28 | 2.78 (−1.53, 7.09) | 0.203 | |
| Post-treatment | 7.55 ± 4.98 | 12.40 ± 7.74 | −4.86 (−7.84, −1.87) | 0.002
| 0.66 |
Values are expressed as mean ± standard deviation for baseline and immediate post-treatment and as mean (95% confidence interval) for inter-group change scores. Abbreviations: ODI = Oswestry Disability Index; RMD = Roland-Morris Low Back and Disability Questionnaire; TSK = Tampa Scale for Kinesiophobia; VAS = Visual Analogue Scale.